Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso

Introduction As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug press...

Full description

Saved in:
Bibliographic Details
Main Authors: Issiaka Soulama, Adama Baguiya, Seni Kouanda, Mohamadou SIRIBIE, André-Marie Tchouatieu, Jean Moise Tanga Kaboré, Yacouba Nombré, Denise Hien, Alice Kiba Koumaré, Nouhoun Barry, Alimatou Héma, Frédéric Dianda, Yacouba Savadogo, Alfred Bewendtaoré Tiono, Sodiomon Bienvenu Sirima
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/2/e040220.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846165872850239488
author Issiaka Soulama
Adama Baguiya
Seni Kouanda
Mohamadou SIRIBIE
André-Marie Tchouatieu
Jean Moise Tanga Kaboré
Yacouba Nombré
Denise Hien
Alice Kiba Koumaré
Nouhoun Barry
Alimatou Héma
Frédéric Dianda
Yacouba Savadogo
Alfred Bewendtaoré Tiono
Sodiomon Bienvenu Sirima
author_facet Issiaka Soulama
Adama Baguiya
Seni Kouanda
Mohamadou SIRIBIE
André-Marie Tchouatieu
Jean Moise Tanga Kaboré
Yacouba Nombré
Denise Hien
Alice Kiba Koumaré
Nouhoun Barry
Alimatou Héma
Frédéric Dianda
Yacouba Savadogo
Alfred Bewendtaoré Tiono
Sodiomon Bienvenu Sirima
author_sort Issiaka Soulama
collection DOAJ
description Introduction As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients’ life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.Methods and analysis We plan to conduct a quasi-experimental study in the Kaya health district in Burkina Faso. We will investigate a simultaneous deployment of three ACTs, artemether–lumefantrine, pyronaridine–artesunate, dihydroartesinin–piperaquine, targeting three segments of the population: pregnant women, children under five and individuals aged five years and above. The study will include four overlapping phases: the formative phase, the MFT deployment phase, the monitoring and evaluation phase and the post-evaluation phase. The formative phase will help generate baseline information and develop MFT deployment tools. It will be followed by the MFT deployment phase in the study area. The monitoring and evaluation phase will be conducted as the deployment of MFT progresses. Cross-sectional surveys including desk reviews as well as qualitative and quantitative research methods will be used to assess the study outcomes. Quantitatives study outcomes will be measured using univariate, bivariate and multivariate analysis, including logistic regression and interrupted time series analysis approach. Content analysis will be performed on the qualitative data.Ethics and dissemination The Health Research Ethics Committee in Burkina Faso approved the study (Clearance no. 2018-8-113). Study findings will be disseminated through feedback meetings with local communities, national workshops, oral presentations at congresses, seminars and publications in peer-reviewed scientific journals.Trial registration number NCT04265573.
format Article
id doaj-art-ebd3880069bd4deca86864af5e6dc7d5
institution Kabale University
issn 2044-6055
language English
publishDate 2021-02-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-ebd3880069bd4deca86864af5e6dc7d52024-11-17T04:25:09ZengBMJ Publishing GroupBMJ Open2044-60552021-02-0111210.1136/bmjopen-2020-040220Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina FasoIssiaka Soulama0Adama Baguiya1Seni Kouanda2Mohamadou SIRIBIE3André-Marie Tchouatieu4Jean Moise Tanga Kaboré5Yacouba Nombré6Denise Hien7Alice Kiba Koumaré8Nouhoun Barry9Alimatou Héma10Frédéric Dianda11Yacouba Savadogo12Alfred Bewendtaoré Tiono13Sodiomon Bienvenu Sirima14Département Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoKaya Health and Demographic Surveillance System (Kaya-HDSS), Ouagadougou, Burkina FasoInstitut de Recherche en Sciences de la santé, Centre National de la Recherche Scientifique et Technologique, Ouagadougou, Burkina FasoDépartement Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoMedicines for Malaria Venture, Geneva, SwitzerlandDépartement Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoProgramme National de Lutte contre le Paludisme, Ministère de la Santé, Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoProgramme National de Lutte contre le Paludisme, Ministère de la Santé, Ouagadougou, Burkina FasoDépartement Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoDépartement Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoProgramme National de Lutte contre le Paludisme, Ministère de la Santé, Ouagadougou, Burkina FasoProgramme National de Lutte contre le Paludisme, Ministère de la Santé, Ouagadougou, Burkina FasoDépartement Biomédical et Santé Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina FasoGroupe de Recherche Action en Santé, Ouagadougou, Burkina FasoIntroduction As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients’ life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.Methods and analysis We plan to conduct a quasi-experimental study in the Kaya health district in Burkina Faso. We will investigate a simultaneous deployment of three ACTs, artemether–lumefantrine, pyronaridine–artesunate, dihydroartesinin–piperaquine, targeting three segments of the population: pregnant women, children under five and individuals aged five years and above. The study will include four overlapping phases: the formative phase, the MFT deployment phase, the monitoring and evaluation phase and the post-evaluation phase. The formative phase will help generate baseline information and develop MFT deployment tools. It will be followed by the MFT deployment phase in the study area. The monitoring and evaluation phase will be conducted as the deployment of MFT progresses. Cross-sectional surveys including desk reviews as well as qualitative and quantitative research methods will be used to assess the study outcomes. Quantitatives study outcomes will be measured using univariate, bivariate and multivariate analysis, including logistic regression and interrupted time series analysis approach. Content analysis will be performed on the qualitative data.Ethics and dissemination The Health Research Ethics Committee in Burkina Faso approved the study (Clearance no. 2018-8-113). Study findings will be disseminated through feedback meetings with local communities, national workshops, oral presentations at congresses, seminars and publications in peer-reviewed scientific journals.Trial registration number NCT04265573.https://bmjopen.bmj.com/content/11/2/e040220.full
spellingShingle Issiaka Soulama
Adama Baguiya
Seni Kouanda
Mohamadou SIRIBIE
André-Marie Tchouatieu
Jean Moise Tanga Kaboré
Yacouba Nombré
Denise Hien
Alice Kiba Koumaré
Nouhoun Barry
Alimatou Héma
Frédéric Dianda
Yacouba Savadogo
Alfred Bewendtaoré Tiono
Sodiomon Bienvenu Sirima
Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
BMJ Open
title Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
title_full Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
title_fullStr Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
title_full_unstemmed Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
title_short Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso
title_sort protocol for a quasi experimental study to assess the feasibility acceptability and costs of multiple first lines artemisinin based combination therapies for uncomplicated malaria in the kaya health district burkina faso
url https://bmjopen.bmj.com/content/11/2/e040220.full
work_keys_str_mv AT issiakasoulama protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT adamabaguiya protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT senikouanda protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT mohamadousiribie protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT andremarietchouatieu protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT jeanmoisetangakabore protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT yacoubanombre protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT denisehien protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT alicekibakoumare protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT nouhounbarry protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT alimatouhema protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT fredericdianda protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT yacoubasavadogo protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT alfredbewendtaoretiono protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso
AT sodiomonbienvenusirima protocolforaquasiexperimentalstudytoassessthefeasibilityacceptabilityandcostsofmultiplefirstlinesartemisininbasedcombinationtherapiesforuncomplicatedmalariainthekayahealthdistrictburkinafaso